Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting

Jun 22 2017

• By Michael Cipriano

FDA entrance sign 2016

Related Content

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

May 26 2017

REMS Class-Action Lawsuit Against Celgene Is First By Patients

Jun 20 2017

FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

Jun 08 2017

Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says

Jun 12 2017

Gottlieb Talks Activist Role For FDA In Curbing REMS Abuse

Jun 21 2017

Related Companies

Bristol Myers Squibb Company

Additional Topics

United States Generic Drugs Pricing Debate Intellectual Property Regulation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window